The association between direct oral anticoagulant concentration upon acute stroke and stroke outcome.

[1]  C. Hong,et al.  Safety and efficacy of endovascular thrombectomy in acute ischemic stroke treated with anticoagulants: a systematic review and meta-analysis , 2022, Thrombosis Journal.

[2]  W. Haefeli,et al.  Low Exposure to Direct Oral Anticoagulants Is Associated with Ischemic Stroke and Its Severity , 2022, Journal of stroke.

[3]  A. Camm,et al.  2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[4]  Jinkwon Kim,et al.  Initial Stroke Severity in Patients With Atrial Fibrillation According to Antithrombotic Therapy Before Ischemic Stroke , 2020, Stroke.

[5]  Sung-Chun Tang,et al.  Using the PCI-IS Method to Simultaneously Estimate Blood Volume and Quantify Nonvitamin K Antagonist Oral Anticoagulant Concentrations in Dried Blood Spots. , 2020, Analytical chemistry.

[6]  Sung-Chun Tang,et al.  Real‐World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation , 2019, Clinical pharmacology and therapeutics.

[7]  S. Schwab,et al.  Direct Oral Anticoagulant Plasma Levels for the Management of Acute Ischemic Stroke , 2019, Cerebrovascular Diseases.

[8]  S. Schwab,et al.  Cerebral Ischemia in Patients on Direct Oral Anticoagulants: Plasma Levels Are Associated With Stroke Severity , 2019, Stroke.

[9]  R. Testa,et al.  Low drug levels and thrombotic complications in high‐risk atrial fibrillation patients treated with direct oral anticoagulants , 2018, Journal of thrombosis and haemostasis : JTH.

[10]  Eric E. Smith,et al.  Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality , 2018, JAMA.

[11]  Michael J Pencina,et al.  Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation , 2017, JAMA.

[12]  Pei-Wen Huang,et al.  Complexity of Heart Rate Variability Can Predict Stroke-In-Evolution in Acute Ischemic Stroke Patients , 2015, Scientific Reports.

[13]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[14]  D. Atar,et al.  Mass screening for silent atrial fibrillation in high risk patients - preliminary results from the STROKESTOP trial , 2013 .

[15]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[16]  Eric E. Smith,et al.  Defining hematoma expansion in intracerebral hemorrhage , 2011, Neurology.

[17]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[18]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[19]  T Brott,et al.  The ABCs of measuring intracerebral hemorrhage volumes. , 1996, Stroke.